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Moreover, HrQoL (DLQI) improved by 65% from inclusion. The conventional system-
ics cohort showed comparable reduction in PASI= 3.1 (77%) but less improvement 
in DLQI= 3.1 (49%). ConClusions: PsoBest provides long-term real-world data on 
psoriasis care in Germany. The results show the high burden of psoriasis patients 
entering the registry and also the high quality of care and patient benefit after 
initiation of systemic treatment.
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objeCtives: Access to multi-country physician panels is an alternative option to 
recruit medical sites for health outcome or post-approval studies, compared to the 
conventional approach of individually recruiting clinical expert sites. The objec-
tive of our study was to assess the potential of physician panels for site recruit-
ment. Methods: In 2012, a representative survey among members of a managed 
physician panel (All Global’s managed panel of ophtalmologists in US, UK, GER, FR, 
IT and SP) was conducted. The survey assessed the willingness of the physicians 
to participate in post-approval studies. Information about former participation in 
those studies and commitment to special requests for post-approval studies (e.g. 
ethical committee involvement, advent reporting to sponsor, security of patient’s 
informed consent) were also collected. Results: A total of 200 opthalmologists 
participated in the survey. Since no special incentive was offered for participation 
the response rate of more than 25% was satisfactory. 79 (39,5%) of the physicians 
formerly participated in clinical trials and 95 (47,5%) in post-approval studies. 54,5% 
of the ophtalmologists were willing to participate in future studies. More than 80% 
of this group was ready to ask their hospital or other legal authorities for permission 
to participate in studies of this kind, to report serious adverse events to the spon-
sor of the study and to ask patients for written informed consent. ConClusions: 
Managed physician panels are a valuable alternative option to recruit medical sites 
for post-approval or health outcome studies. Every second ophtalmologist from 
panels is experienced in this kind of studies and most of them are willing fullfil all 
necessary legal and quality requirements. In addition to timing and cost factors, an 
adavantage of physician panels is the better representation of daily medical routine-
practice, adding to the epidemiological validity of respective projects.
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objeCtives: Clinical experience indicates that edema often remain undiagnosed. 
The aim of this study was to examine how much time passes between impor-
tant events in the ‘patient journey’ and what predicts late consultation and diag-
nosis. Methods: Sixty-five patients with secondary arm lymphedema and 161 
patients with primary or secondary leg lymphedema were interviewed. The follow-
ing latency times were computed: time between 1) first symptoms and first visit 
to physician; 2) visit to physician and diagnosis; 3) diagnosis and lymph drainage 
therapy; and 4) diagnosis and compression therapy. Associations of latency times 
with patient and clinical characteristics were analysed using t tests and multivari-
ate linear regression. Results: All arm edema patients had consulted a physician 
in the year after first symptoms at the latest, and everyone except two received the 
diagnosis in the following year at the latest. For secondary leg edema, the average 
latency until physician consultation was also short with 0.5 ± 1.8 years, and latency 
until diagnosis was 1.7 ± 3.8 years. In contrast, latencies in primary leg edema 
were significantly longer: The average time between first symptoms and physician 
consultation was 5.2 ± 11.0 years, and edema diagnosis was made after further 6.7 
± 11.4 years. On average, it took 13.5 years from first symptoms to lymph drainage 
therapy in these patients and 13.7 years until compression therapy. Predictors of 
late consultation and late diagnosis in primary leg edema were age< 40, positive 
family anamnesis, and female gender. ConClusions: Primary leg lymphedema 
are diagnosed late in many cases, especially in younger women.
PSS57
adheRence By SPaniSh RetinologiStS to the guidance foR 
the management of PatientS With Wet age-Related maculaR 
degeneRation
Colomé A.1, Balaña M.1, Ruiz Moreno J.M.2, Roura M.1
1Novartis Farmacéutica, S.A., Barcelona, Spain, 2Instituto Oftalmológico Alicante (VISSUM) y 
Universidad de Castilla la Mancha, Alicante, Spain
objeCtives: To assess the adherence by Spanish retinologists to the recommenda-
tions for the management of age-related macular degeneration (AMD) published by 
the Spanish Society of Retina and Vitreous (SERV). Methods: Non-interventional, 
retrospective and multicenter study, involving 59 researchers from different Spanish 
Ophthalmology Services that collected medical records from 346 patients aged ≥ 50 
years and diagnosed with exudative AMD. Results: Adherence to SERV-guidelines 
by Spanish retinologists was high concerning diagnostic (96.8%) and control items 
(98.6%) of AMD patients, slightly lower for therapeutic issues (84.4%), and much 
lower on patient follow-up and retreatment criteria (46.9%). When focusing on diag-
nostic, first symptoms indicative of wet AMD were sharp and progressive loss of 
visual acuity (64.7%), followed by metamorphopsia (distorted vision) (33.8%) and 
central scotoma (23.1%). Main diagnostic confirmatory tests were visual acuity 
(97.1%), OCT (93.4%), biomicroscopy (92.2%) and fluorescein angiography (71.1%). 
For therapeutic issues, first choice treatment was based on anti-VEGF-drugs (99.1%), 
mainly ranibizumab (96.8%) as a loading dose of three injections (88.1%). Main 
patient follow-up tests were: visual acuity tests (98.0%), optical coherence tomog-
raphy (96.0%), biomicroscopy (91.9%). Most common control schemes during the 
first year of treatment were every-two-months (35.8%) or monthly (30.4%) visits; 
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objeCtives: The registry “PsoBest” observes systemic therapy of moderate and 
severe psoriasis/psoriasis-arthritis in Germany since 2008. The registry is supported 
by the German society for dermatologists, the association of dermatologists, phar-
maceutical manufactures, dermatologists and patients. It is located at CVderm and 
documents safety, effectiveness and patient benefit in routine health care. One 
purpose of PsoBest is to monitor the safety of systemic antipsoriatics. Methods: 
Patients receiving first time a conventional systemic or biologic treatment are 
observed for 5 years, regardless of therapy switches. Standardised questionnaires 
for physicians and patients are compiled. Adverse and serious adverse events (AE/
SAE) are coded in MedDRA and analyzed twice a year. Results: Pharmacovigilance 
after 42 months on 1984 patients with 800 expositions to biologics (1196 patient 
years) and 1430 to systemics (1548 patient years) resulted in 187 SAE codings in 
121 patients (6.1%). A total of 105 SAE were observed under biologic and 95 under 
conventional systemic treatment (8.9 and 4.5%, respectively). Of these, 20 SAE in 14 
patients were observed in combined treatment. By system-organ-classes, general 
disorders and administration site conditions were observed for 2.3% of biologic 
(1.51 events/100 patient years) and 1.3% systemic patients (1.32 events/100 patient 
years). The rates for cardiac disorders were 0.92 (1.4% of patients) and 0.84 (0.9% 
of systemic patients), respectively. For infections and infestations the rates were 
0.84 (1.3%) and 0.52(0.8%) and for neoplasms benign, malignant and unspecified 
(incl. cysts and polyps) 0.67 (1.0%) and 0.71 (0.8%). ConClusions: PsoBest provides 
urgently needed long-term safety data in the systemic treatment of psoriasis and 
psoriatic-arthritis from routine care in Germany. To date, no safety concern emerged 
from the registry. To raise the power for signal detection, verification, analysis and 
assessment, PsoBest is proactively contributing to the European surveillance of 
effectiveness and safety of systemic psoriasis therapy (ENCEPP-network psonet).
PSS53
afliBeRcePt in neovaSculaR (Wet) age-Related maculaR 
degeneRation: an analySiS of the PayeR deciSion landScaPe
Brown A.1, Ferreira A.2, Lamle S.2, Milnes F.2
1Abacus International, Manchester, UK, 2Novartis Pharma AG, Basel, Switzerland
objeCtives: To investigate and analyse decisions of Health Technology Assessment 
or national drug reimbursement agencies for aflibercept in neovascular (wet) aged-
related macular degeneration, including decision outcomes, the rationale for these, 
the data package and any payer critique of the manufacturer approach. Methods: 
A search of decision-making agency websites in key European markets, Canada and 
Australia was conducted to identify relevant decisions. Data were extracted and used 
to conduct a qualitative analysis of decisions. Results: Five decisions were identi-
fied; from NICE (England & Wales), SMC (Scotland), HAS (France), G-BA (Germany) and 
PBAC (Australia). In all instances, the clinical and economic arguments, where appli-
cable, were based on demonstration of non-inferiority of aflibercept to an existing 
therapy, ranibizumab. These arguments were supported by two key trials of aflibercept 
vs. ranibizumab: VIEW 1 and 2, and also indirect comparisons and network meta-
analyses. In all decisions, aflibercept was either recommended for the full licensed 
indication or recommended with restrictions. All agencies commented that the key 
trials were well conducted and unbiased; however, they also state that the dosing 
schedule for ranibizumab did not reflect the license or clinical practice in respective 
markets, and it was unclear if there would be any difference in the frequency of 
injections between therapies in the clinical setting. Furthermore, for the economic 
models for NICE, SMC and PBAC, the respective agencies thought the frequency of 
injections and number of clinician visits for ranibizumab were overestimated. All 
agencies concluded that aflibercept demonstrated no additional clinical benefit over 
ranibizumab. For example, HAS in France granted an ASMR level V: no improvement 
in clinical benefit, while NICE recommended that aflibercept be used in accordance 
with their recommendations for ranibizumab. ConClusions: While aflibercept is 
an effective alternative therapy to ranibizumab, payers have concluded that it offers 
no demonstrable added clinical benefit compared with ranibizumab.
PSS54
health Related Quality of life-outcome in national caRe - Real 
WoRld data fRom the geRman PSoRiaSiS-RegiStRy “PSoBeSt”
Purwins S.1, Spehr C.1, Augustin M.1, Radtke M.A.1, Reich K.2, Rustenbach S.J.1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Dermatologikum 
Hamburg, Hamburg, Germany
objeCtives: The registry “PsoBest” observes systemic therapy of moderate and 
severe psoriasis/psoriasis-arthritis in Germany since 2008. The registry is supported 
by the German society for dermatologists, the association of dermatologists, phar-
maceutical manufactures, dermatologists and patients. It is located at CVderm and 
records efficacy, safety, and patient benefit in routine health care. One purpose of 
PsoBest is to monitor health related quality of life (HrQoL) and severity of psoria-
sis in the process of care. Methods: Patients receiving first time a conventional 
systemic or biologic therapeutic are observed for 5 years, independent of further 
treatment. Standardised questionnaires for physicians and patients are compiled. 
Main outcomes are severity (PASI), affected body surface area (BSA) and HrQoL (DLQI 
and EQ-5D). Results: A total of 1,984 patients were enrolled up to July 2012 (60% 
male, mean age of 47 years); mean duration of illness was 19±14 years. Patients on 
biologics (n= 686) tended to be male (63 v. 58%), older (48.1 v. 46.7 years) as patients 
on conventional systemics (n= 1,298) and had a longer history of psoriasis (21.9 v. 
16.8 years). The biologic cohort showed more nail involvement (64 v. 52%), signs 
of arthritis (47 v. 17%), higher severity (PASI: 15.6 v. 14.6; BSA: 22. v. 21.5) and lower 
HrQoL (DLQI: 11.7 v. 11.0; EQ-5D VAS: 50.6 v. 55.7). For the biologics cohort, mean 
PASI improved to 4.5 between 12 and 24 months (reduction of 70% from baseline). 
